Art

J-GLOBAL ID：202102212371773434   Reference number：21A0417016

Acute Myocardial Infarction in an Adolescent Receiving Anagrelide for Essential Thrombocythemia with Underlying Persistent Coronary Endothelial Dysfunction

根底にある持続性冠動脈内皮機能障害を伴う本態性血小板血症に対するアナグレリドの投与を受けている青年の急性心筋梗塞

Author (11)： Tanaka Ryuhei (Department of Pediatric Hematology/Oncology, Saitama Medical University International Medical Center) ,  Gatate Yodo (Department of Cardiology, Saitama Medical University International Medical Center) ,  Sujino Yasumori (Department of Cardiology, Saitama Medical University International Medical Center) ,  Todo Maki (Department of Pharmacy, Saitama Medical University International Medical Center) ,  Ohta Atsuhiko (Department of Pediatric Hematology/Oncology, Saitama Medical University International Medical Center) ,  Shimizu Yuki (Department of Pediatric Hematology/Oncology, Saitama Medical University International Medical Center) ,  Watanabe Atsuko (Department of Pediatric Hematology/Oncology, Saitama Medical University International Medical Center) ,  Naganuma Ken (Department of Pediatric Hematology/Oncology, Saitama Medical University International Medical Center) ,  Muramatsu Toshihiro (Department of Cardiology, Saitama Medical University International Medical Center) ,  Fukushima Kenji (Department of Nuclear Medicine, Saitama Medical University International Medical Center) ,  Nakano Shintaro (Department of Cardiology, Saitama Medical University International Medical Center)
Material： International Heart Journal (Web)
Volume： 61  Issue： 6  Page： 1289-1293(J-STAGE)  Publication year： 2020 
JST Material Number： U1357A  ISSN： 1349-3299  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： human ,...
Semi thesaurus term： genetic variation ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=21A0417016&from=J-GLOBAL&jstjournalNo=U1357A") }}

Author keywords (2)： Oncocardiology ,  Acute coronary syndrome

JST classification (3)： Congenital diseases,deformities in general.  (GD03010V) ,  Drug therapy(=pharmacotherapy)for hematologic diseases in general  (GK05020P) ,  Cardiovascular system diseases  (GJ03000C)

Substance index (1)： Anagrelide

Reference (23)：

• 1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391-405.
• 2. Tefferi A, Pardanani A. Essential thrombocythemia. N Engl J Med 2019; 381: 2135-44.
• 3. Falanga A, Marchetti M. Thrombosis in myeloproliferative neoplasms. Semin Thromb Hemost 2014; 40: 348-58.
• 4. Gugliotta L, Tieghi A, Tortorella G, et al. Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia. Leuk Res 2011; 35: 1557-63.
• 5. Birgegård G, Besses C, Griesshammer M, et al. Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of anagrelide Efficacy and Long-term safety study. Haematologica 2018; 103: 51-60.

Terms in the title (8)： 持続性 ,  冠動脈 ,  内皮機能障害 ,  本態性血小板血症 ,  アナグレリド ,  投与 ,  青年 ,  急性心筋梗塞